The Lancet Respiratory Medicine

Dupilumab Outperforms Omalizumab in First Head-to-Head Trial for Severe CRSwNP with Asthma: Study

DRRA17 hours ago01 mins

Dupilumab Outperforms Omalizumab in First Head-to-Head Trial for Severe CRSwNP with Asthma: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link

Symptoms Predict Exacerbation Risk in Bronchiectasis, Suggesting Expanded Role for Macrolide Therapy: Study Finds

DRRA1 month ago01 mins

Symptoms Predict Exacerbation Risk in Bronchiectasis, Suggesting Expanded Role for Macrolide Therapy: Study Finds We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link

Coverage of Sarepta Duchenne drug may be halted by N.Y. state Medicaid

Oragenics partners Receptor.AI for brain health candidate portfolio

Goa court grants bail to doctor accused of sexual assault on ICU patient

Decomposed body found in Deoria Medical College water tank

Hikma and Celltrion Partner to Commercialize Biosimilars Across the MENA Region

India flags testing lapses at pharma firms after cough syrups deaths

The Lancet Respiratory Medicine

Dupilumab Outperforms Omalizumab in First Head-to-Head Trial for Severe CRSwNP with Asthma: Study

Symptoms Predict Exacerbation Risk in Bronchiectasis, Suggesting Expanded Role for Macrolide Therapy: Study Finds